After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...